Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Fullfathom, this is and will be an epic company to be in. Plus just think of all the people will help.
I think the issue at the moment is AIM.
Yesterday’s 15-16% rise got pulled back to 4-5% and today’s 10% rise got pulled back to 2-3%. 6-8 brilliant RNS’s on trials, patents and more since august. Many companies on a whiff of any sort of RNS like ours fly. Clearly they want to make it difficult for TILS in my opinion. But here is to the big move and to a brilliant end of year plus 2021 :) GLA
RNS stopped having an impact from the 2nd of August. The first trading day after the announcement to move from AIM. I believe this has halted some progress. I look forward to the move and then more news. As for now it’s hard to hold onto any % gain. Yes we saw another spike to £2ish, but demerger related.
BMO3, that’s my train of thought. The ability to STICK to timelines.
Demerger was late, trials late, main market move is late, so now we’ve been told trials results by end of year, do we believe them?
LTH are in and will be for the foreseeable, it’s the new investors....
Inability to stick to timelines has played into hands of MM and our ever happy shorters
BMO3, it’s been 3 weeks today since the call.
Very frustrating considering we were told it was “imminent”
I mailed and usually get a response. This time radio silence :(
BMO3, couldn’t bloody agree more. We’ve been painted as a COVID stock, but those who’ve bothered to research know better.
Covid is a bonus. TIlS is so more than this, shame many don’t bother to read up.. Foralumab could be a revolutionary treatment just a naming a few: (So those that don’t know, READ UP)
*Multiple sclerosis (pro-MS)
*Crohn's disease
*Neurodegenerative diseases, including Alzheimer's disease
*Inflammatory Bowel Disease
*MERS
Brazil trial will validate its efficacy and make 2021 all the more exciting.
Not sure if already posted. WHO lols to be doubling down on MAB & Dexamethasone
https://www.reuters.com/article/health-coronavirus-who-drugs-exclusive-i-idUSKBN27L1PE
Wes_Sam, we all hope for an announcement in regards to the main market move. It was mentioned in the DR investor call two weeks ago now that it was “imminent”
IMO a lot of games have been played since the 2nd of August, first trading day after main market announcement. Combined with the BOD causing a CF of the demerger it’s played into the MM hands and they know it, and may well continue until a date is announced.
Kind of like having a bird saying she’s gonna leave you, but she’s not sure when. You’re not gonna make it nice are you? :) GLA
Yet another day of more late big buys being posted after close.
Such constant and systematic abuse. I really believe this is due to the MM’s having no incentive to make a market or play ball due to TILS leaving for the main exchange.
I further believe that the company has an obligation to its shareholders to investigate such abuses and formally file a complaint to the FCA. IMO
TILS is a target, for sure. Foralumab shows any postive signs then big pharma will move in I believe. Foralumab has the potential to impact many diseases/illnesses that have over $100 billion combined market revenue. IMO
Rockz, the DR and BOD need to update investors and market with main market move dates.
It was announced months ago now and was mentioned two weeks ago.
Announcement was made on 30th July and from then the decline started the Monday after. Since then we had lots of good news.
But AIM MM’s have been throwing their toys out.
Lurking, agree, no announcement should have been made without a leaving date and 20 day notice. Such an error.
“We are leaving, don’t know when, but sometime ermmmm in the future”
2 weeks ago now we were told main market move was imminent!!
So interesting observation, maybe someone can help explain.
Largest shorting was yesterday at 27%, however the NAS went up.
Can they short just AIM?
It’s a cracking interview. Really spelt it out and the potential impact Foralumab could have on many many diseases/illnesses. COVID trial really a tester of Foralumab efficacy and their nasal and inhalation methods ready for bigger trials in 2021.
GC on Bloomberg over the pond this afternoon
https://streamable.com/xg2fxh
As predicted. Late buys being reported. Nice £85k buy at 128
Lots of buying down at these levels and they dragged it down twice from 135, plus NAS way ahead.
Demerger and now moving shortly.
Hopefully all behind us. Few months ago we were in the 120’s without Accustem shares and no trial start. GLA
Could be.
That and MM’s spitting their dummy’s out TILS is being moved from AIM with Accustem moving to main exchange too
Watch all the delayed trades on close of market.
Can’t wait for the main market move which shouldn’t be too far away.
Paul, one thing I’ve realised is with this share the last few months is most times it has the opportunity to rise it doesn’t, or does to be pulled back. But every opportunity to fall, it’s does so.
Never seen this before or at this level.
The same Dr told us main market move was due imminently (any day). It’s been 10 days since.
Yet let’s not forget news was daily when placing was being primed. All i can think is that last month we were at 120’s, at least now we are at the 140’s and with Accustem shares.
As Y-Alam said, news cannot be held in order to play a game. It must be released.